UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.

UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.

UMN's pandemic influenza vaccine, UMN-0501 designated as orphan drug.

UMN Pharma presents at DIGESTIVE DESEASE WEEK 2008 in San Diego, California.

UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.

UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN’s pandemic influenza vaccine.

UMN Pharma appoints Mr. Masahiro Hayashi as a new Director of the company.